Power analyses of moment analysis parameter in bioequivalence tests

Area of Science:

• Pharmacokinetics
• Drug bioavailability assessment
• Bioequivalence testing

Background:

• Bioequivalence studies are crucial for generic drug approval.
• Assessing the rate of drug absorption is a key component of bioequivalence.
• Current parameters like time to peak concentration (tmax) have limitations.

Purpose of the Study:

• To evaluate Mean Residence Time (MRT) as a parameter for estimating bioavailability rate in bioequivalence tests.
• To compare the statistical performance of MRT with tmax, AUCt, and Cmax.
• To assess the impact of data variability on the reliability of MRT.

Main Methods:

• Utilized simulated and experimental pharmacokinetic data.
• Calculated and compared MRT (MRTt and MRT infinity) with tmax, AUCt, and Cmax.
• Employed statistical analysis to determine the power of each parameter.
• Investigated the effect of plasma concentration variances using simulation.

Main Results:

• MRT showed sufficient sensitivity to absorption rate variations, despite being influenced by elimination rate.
• MRTt exhibited higher statistical power than MRT infinity, especially when the flip-flop phenomenon occurred.
• The statistical power of MRTt was comparable or superior to AUCt and Cmax in simulated data.
• Variances in plasma concentrations, even near the last sampling time, did not significantly impact MRTt's power.

Conclusions:

• MRTt is a reliable parameter for estimating bioavailability rate in bioequivalence studies.
• MRTt can serve as a viable alternative to tmax for assessing drug absorption rates.
• The robustness of MRTt to data variability enhances its utility in bioequivalence testing.